Nuclear Healthcare Ltd, a division of Thyrocare Group, is planning to set up 120 molecular imaging centres by 2015 for low cost cancer diagnosis services with an investment of around Rs 1,000 crore. The company has announced a strategic partnership with GE Healthcare to facilitate 120 advanced PET/CT imaging systems and 12 PET Trace Medical Cyclotrons for early detection of cancer.
It would set up the centres in three phases in hub and spoke model and has already invested Rs 100 crore for setting up facilities in Mumbai, Delhi and Coimbatore, said A Velumani, founder and managing director of Nuclear Healthcare Ltd.
“We expect an investment of around Rs 1,000 crore to go into the process of setting up the centres,” he said. Of this, almost Rs 300 would be invested through equity while the rest of Rs 700 crore would come from debt.
On the equity part, around 35 per cent investment would come from Velumani, another 35 per cent from private equity player Cx Partners, which acquired around 27 per cent stake in Thyrocare, and around 30 per cent from Thyrocare Technologies Ltd.
While Rs 100 crore has already been invested, Rs 100 crore each would be invested in the next two years from the equity partners.
The company expects to break even in the third year, by 2013-14, and expects around Rs 100 crore turnover by 2015-16.
